Apelin Receptor Agonist
Obesity (Exercise Mimetic)
PreclinicalIND Submission anticipated 2026
Key Facts
Indication
Obesity (Exercise Mimetic)
Phase
Preclinical
Status
IND Submission anticipated 2026
Company
About BioAge Labs
Founded in 2015, BioAge Labs leverages its proprietary multi-omics discovery platform to translate insights from human aging biology into a pipeline of novel therapeutics for metabolic diseases. The company has achieved key milestones, including advancing its lead oral NLRP3 inhibitor, BGE-102, into Phase 1b/2a studies for cardiovascular risk and diabetic macular edema, and preparing an IND for its apelin receptor agonist as an exercise mimetic. Its strategy is validated by a recent $115 million public offering, positioning it to execute on its clinical and platform expansion goals through 2026.
View full company profile